News
It's Not Too Late to Buy Dynavax Stock After Its Hepatitis B Vaccine Approval
Some thought this day would never arrive. After two prior failed attempts, Dynavax Technologies (NASDAQ: DVAX) finally won approval for hepatitis B vaccine Heplisav-B. The company announced the....
Better Buy: Acadia Pharmaceuticals vs. Biogen
A potential rising star or an established leader? That's pretty much the choice for investors considering whether to buy Acadia Pharmaceuticals (NASDAQ: ACAD) or Biogen (NASDAQ: BIIB) stock.So far....
Puma Biotechnology Is Down 19% -- Is Its Stock a Bargain?
Despite a fairly strong third-quarter earnings release that hit the wires after the bell Thursday, mid-cap biotech Puma Biotechnology's (NASDAQ: PBYI) shares got pummeled today. Specifically,....
Why Intrexon Corporation Stock Got Crushed Today
Shares of the synthetic-biology company Intrexon Corporation (NYSE: XON) lost over a quarter of their value today -- down 25.63% -- on nearly nine times the average daily volume. The culprit? An....
Momenta Pharmaceuticals, Inc.'s Rough Month
Momenta Pharmaceuticals (NASDAQ: MNTA) has had a rough month or so after seeing Mylan (NASDAQ: MYL) pass it up to get the first approval of a generic version of Teva Pharmaceutical's (NYSE: TEVA)....
Why Immunomedics, Inc. Jumped Higher Today
Immunomedics (NASDAQ: IMMU) is up 19% at 2:21 p.m. EST, after announcing a new CEO following the closing bell yesterday. The company also announced fiscal first-quarter earnings, but the jump in....
This Is Why Omeros Corporation Shares Are Rocketing 33% Higher Today
Despite already rewarding investors with more than a 100% return this year, shares of Omeros Corporation (NASDAQ: OMER) are charging 33.3% higher at 1:45 p.m. EST Friday following the release of....
BOIRON : Formulaire de déclaration mensuelle des droits de vote au 31 octobre 2017
Le 10 novembre 2017
Publication
du nombre d'actions composant le capital et du nombre total de droits de vote
(articles L. 233-8 II du code de commerce et 223-16 du règlement général de....
7 Things AbbVie's Top Executives Just Said That You'll Want to Know
It's a good time to be AbbVie (NYSE: ABBV). And with the biotech's share price up more than 50% year to date, it's a good time to be an AbbVie shareholder. The company reported a strong....
Ionis Pharmaceuticals' Earnings Results Fuel Volatility
Ionis Pharmaceuticals (NASDAQ: IONS) reported third-quarter financials that were better than hoped on Tuesday, but the worry of slowing U.S. sales of Spinraza, a rare disease drug that's licensed....
Why Macy's, Hostess Brands, and Perrigo Jumped Today
The stock market lost ground Thursday as investors reacted negatively to news regarding proposed U.S. corporate and individual income tax cuts. Reports surfaced that the Senate version of tax....
ImmunoGen, Inc. Moves Forward
Like most biotechs without a drug generating revenue, ImmunoGen's (NASDAQ: IMGN) third-quarter earnings were a review of what it's accomplished and a look at what investors can expect in the....
The Not-So-Subtle Reason Behind Perrigo Company PLC's 13% Move Higher
Shares of Perrigo (NYSE: PRGO), a provider of consumer goods and over-the-counter pharmaceutical products, rocketed higher by as much as 13% during Thursday's trading session after the company....
Why Inovio Pharmaceuticals Inc. Is Sinking Today
In response to the company reporting disappointing third-quarter results, shares of Inovio Pharmaceuticals (NASDAQ: INO), a clinical-stage biotech focused on vaccines, fell 14% as of 2:15 p.m. EST....
Why Idera Pharmaceuticals Inc. Jumped Higher Today
Idera Pharmaceuticals (NASDAQ: IDRA) is up 14% at 11:46 a.m. EST after releasing data from a phase 1/2 trial testing its drug candidate IMO-2125 in combination with Bristol-Myers Squibb's (NYSE:....
2 Antidepressant-Focused Biotech Stocks Are Surging Today. Here's Why.
Shares of SAGE Therapeutics Inc. (NASDAQ: SAGE) are rocketing higher today in response to positive clinical trial data for a postpartum depression candidate. Investors are pushing up Marinus....
Healthcare: Is Valeant Pharmaceuticals the Turnaround Story of the Century?
This week, Valeant Pharmaceuticals (NYSE: VRX) reported its earnings, and the market rewarded it with a 17% stock price bump. While the company's shares are still down 95% from their 2016 highs,....
Here's Why the Best Is Yet to Come for Novavax, Inc.
Synthetic vaccine maker Novavax (NASDAQ: NVAX) has fallen on hard times. The dramatic failure of its closely watched respiratory syncytial virus fusion (RSV F) vaccine in elderly adults last year....
What You Need to Know From Inovio Pharmaceuticals' Q3 Update
Inovio Pharmaceuticals (NASDAQ: INO) continues to take investors on a roller coaster ride. The biotech stock was up close to 25% by late May, only to give up all of those gains and then some. A....
Editas Medicine Keeps Moving Forward
Editas Medicine (NASDAQ: EDIT) announced third-quarter 2017 results on Wednesday after the market closed, and shares of the CRISPR gene-editing specialist were down modestly on Thursday in....
You'll Be Stunned by Gilead Sciences CEO's Prediction for 2018
No, this isn't one of those clickbait articles you've no doubt seen way too many times. Gilead Sciences (NASDAQ: GILD) CEO John Milligan actually did make a prediction about 2018. And it really....
This Gene Therapy Can Restore Vision, but Will It Break the Bank?
In October, Spark Therapeutics (NASDAQ: ONCE) took another step closer to FDA approval for its vision-restoring drug, Luxturna. An approval for the gene-editing therapy early next year would be a....
Here's What Overshadowed Valeant Pharmaceuticals in October, Pushing Its Shares Down 18%
Shares of Valeant Pharmaceuticals (NYSE: VRX), an embattled drug developer that's primarily grown through price hikes and acquisitions over the years, tumbled 18% during October, according to data....
Why Five Prime Therapeutics Stock Is on the Rebound Today
After a whopping 41% drop yesterday, shares of the clinical-stage biotech Five Prime Therapeutics (NASDAQ: FPRX) are on the mend today as the result of an upbeat clinical update. Specifically,....
The Bottom Line on Why Pacira Pharmaceuticals Inc. Rocketed Higher by as Much as 24%
Shares of Pacira Pharmaceuticals (NASDAQ: PCRX), which focuses on developing medicines to be used in the ambulatory or surgical setting, surged by as much as 24% during Wednesday's trading session....